Literature DB >> 10082073

Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus.

C McGrath1, A Buist, T R Norman.   

Abstract

Pregnancy is a time of great emotional change for a woman, producing increased stress and anxiety. Medication may be required for the treatment of anxiety disorders at this time. Given the fact that psychotropic drugs readily cross the placenta and could have important implications for the developing fetus, it is necessary to balance the possible effects of medication against the potential effects to both the mother and fetus if the anxiety disorder is left untreated. Despite the widespread use of psychotropic drugs such as benzodiazepines and antidepressants during pregnancy, there is a paucity of information regarding the effect of such exposure on the developing fetus. From a review of the literature it is clear that the issue of safety of psychotropic drugs during pregnancy is far from resolved. While some of the findings from animal studies are alarming, these studies cannot be directly extrapolated to humans. In addition, varying sample sizes and multiple drug exposures further complicate interpretation of human studies. Nonpharmacological treatments such as cognitive behavioural therapy should be employed whenever possible for the treatment of anxiety disorders during pregnancy. However, if medication is required pregnant women should be prescribed the lowest dosage for the minimum amount of time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082073     DOI: 10.2165/00002018-199920020-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  102 in total

1.  Effects of exposure of pregnant mice to chlordiazepoxide (CDP) on the development and ultrasound production of their offspring.

Authors:  H Kurishingal; P Palanza; P F Brain
Journal:  Gen Pharmacol       Date:  1992-01

2.  Possible teratogenicity of imipramine-chloropyramine.

Authors:  J Idänpään-Heikkilä; L Saxén
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

3.  Rachelefsky GS, Flynt JW Jr,+FLYNT JW JR, Ebbin AJ, Wilson MG, Banister P, Dafoe C, Smith ES, Miller J:Possible teratogenicity of tricyclic antidepressants.

Authors: 
Journal:  Lancet       Date:  1972-04-15       Impact factor: 79.321

4.  Effect of tranquilizing drugs during pregnancy on activity of offspring.

Authors:  D R Hoffeld; J McNew; R L Webster
Journal:  Nature       Date:  1968-04-27       Impact factor: 49.962

5.  Abnormalities in children exposed to benzodiazepines in utero.

Authors:  L Laegreid; R Olegård; J Wahlström; N Conradi
Journal:  Lancet       Date:  1987-01-10       Impact factor: 79.321

Review 6.  Antidepressant treatment during breast-feeding.

Authors:  K L Wisner; J M Perel; R L Findling
Journal:  Am J Psychiatry       Date:  1996-09       Impact factor: 18.112

7.  Behavioural changes in the offspring of rats exposed to diazepam during gestation.

Authors:  R Cagiano; M A De Salvia; M Perischella; G Renna; M Tattoli; V Cuomo
Journal:  Eur J Pharmacol       Date:  1990-02-20       Impact factor: 4.432

8.  The effect of anxiety and depression during pregnancy on obstetric complications.

Authors:  M R Perkin; J M Bland; J L Peacock; H R Anderson
Journal:  Br J Obstet Gynaecol       Date:  1993-07

9.  Lack of relation of oral clefts to diazepam use during pregnancy.

Authors:  L Rosenberg; A A Mitchell; J L Parsells; H Pashayan; C Louik; S Shapiro
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

10.  Effects of prenatal exposure to tricyclic antidepressants on adrenergic responses in progeny.

Authors:  J W Simpkins; F P Field; G Torosian; E E Soltis
Journal:  Dev Pharmacol Ther       Date:  1985
View more
  6 in total

Review 1.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

Review 2.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Medications for panic disorder and generalized anxiety disorder during pregnancy.

Authors:  Sofya M Rubinchik; Anita S Kablinger; J Suzette Gardner
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

4.  Depression, Anxiety, and Pharmacotherapy Around the Time of Pregnancy in Hawaii.

Authors:  Emily K Roberson; Eric L Hurwitz; Dongmei Li; Robert V Cooney; Alan R Katz; Abby C Collier
Journal:  Int J Behav Med       Date:  2016-08

Review 5.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

6.  Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.

Authors:  Walter K Kraft; Eric Gibson; Kevin Dysart; Vidula S Damle; Jennifer L Larusso; Jay S Greenspan; David E Moody; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Pediatrics       Date:  2008-08-11       Impact factor: 7.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.